Research programme: ROR gamma receptor modulators - Karo Pharma/Pfizer

Drug Profile

Research programme: ROR gamma receptor modulators - Karo Pharma/Pfizer

Latest Information Update: 21 Dec 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Karo Bio; Pfizer
  • Developer Karo Pharma AB; Pfizer
  • Class Small molecules
  • Mechanism of Action Nuclear receptor subfamily 1 group F member 3 modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Autoimmune disorders

Most Recent Events

  • 21 Dec 2016 Early research development is ongoing in Sweden (Karo Pharma pipeline, December 2016)
  • 16 Jul 2016 No recent reports of development identified for research development in Autoimmune-disorders in Sweden
  • 26 Jun 2013 Karo Bio and Pfizer extend their collaboration to discover and develop RORgamma modulators for autoimmune disorders
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top